Prostate Cancer - Results from #260

Inhibition of PIM kinase in tumor-associated macrophages suppresses inflammasome activation and sensitizes prostate cancer to immunotherapy. February 24, 2025

Defining The Role for Hormone Therapy in Biochemically Recurrent Prostate Cancer: What Counts as a Win for Patients? February 24, 2025

Validation of a digital pathology-based multimodal artificial intelligence biomarker in a prospective, real-world prostate cancer cohort treated with prostatectomy. February 24, 2025

Stereotactic body radiotherapy (SBRT) as a treatment for localized prostate cancer: a retrospective analysis. February 24, 2025

Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials. February 24, 2025

MRI in Prostate Cancer Screening: A Review and Recommendations, From the AJR Special Series on Screening. February 21, 2025

Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719). February 21, 2025

Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases. February 21, 2025

Photodynamic therapy for the precise treatment of localized prostate cancer. February 21, 2025

Specificity of a polygenic score for aggressive prostate cancer. February 21, 2025

Are Patients with Prostate Imaging Reporting and Data System 5 Lesions Eligible for Active Surveillance? A Multicentric European Study. February 20, 2025

The association between the interval from biopsy to radical prostatectomy and biochemical recurrence in patients with intermediate- and high-risk prostate cancer. February 20, 2025

On-treatment PSA kinetics as a potential biomarker: Guiding personalized treatment in metastatic hormone-sensitive prostate cancer. February 20, 2025

Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy. February 20, 2025

CRISPR screening identifies regulators of enhancer-mediated androgen receptor transcription in advanced prostate cancer. February 20, 2025

Clarity Receives US FDA Fast Track Designation for the Treatment of Metastatic Castration-Resistant Prostate Cancer Patients with Cu-67 SAR-bisPSMA February 19, 2025

Clinical and Translational Results from PORTER, a Multi-cohort Phase 1 Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. February 19, 2025

Is Extraordinary Response and Long-Term Remission of Metastatic Castration-Resistant Prostate Cancer (mCRPC) After [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy Due to an Immunomodulatory Effect (Radiovaccination)? A Dual Center Experience on Super-Responders. February 19, 2025

Social risk factors screening preferences among breast and prostate cancer survivors: A qualitative study. February 19, 2025

Impact of Prostate Cancer Treatment on Quality of Life of LGBTQ+ Patients: A Systematic Review. February 19, 2025

Page 14 of 1473